What is GLP-2 TRZ (Tirzepatide)?
GLP-2 TRZ is Peptora's research designation for Tirzepatide, a single-molecule peptide that simultaneously engages two metabolic receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Because it activates both incretin pathways at once, Tirzepatide is described throughout the literature as a dual GIP/GLP-1 receptor agonist (or dual incretin co-agonist).
Tirzepatide was originally developed by Eli Lilly under the research code LY3298176 and is approved as a medicine under the brand names Mounjaro and Zepbound. Peptora's GLP-2 TRZ is a distinct research-only material intended exclusively for laboratory research — it is not a medicine and is not supplied for human or animal use.
The "GLP-2" naming reflects a lineage researchers find intuitive: single agonists act on one incretin receptor, dual agonists like Tirzepatide on two, and triple agonists on three. Throughout this guide the compound is referred to by its canonical research name, GLP-2 TRZ, with Tirzepatide noted as the underlying compound.
The essentials at a glance
Dual-receptor agonist
One molecule that engages both the GIP and GLP-1 receptors at once.
Two incretin pathways
Combining GIP and GLP-1 signaling in a single peptide is what distinguishes it from single agonists.
Research use only
Studied in metabolic, appetite, and body-weight models — never for human or animal use.
99%+ verified purity
HPLC-verified and confirmed by LC-MS, with a batch-specific certificate of analysis.
How GLP-2 TRZ works: the dual-receptor mechanism
The two receptors GLP-2 TRZ engages are the body's principal incretin receptors — the signaling system that links nutrient sensing to insulin response. Studying them together is what makes the compound distinct from earlier single-receptor research tools:
- GLP-1 receptor — one of the two major incretin receptors, associated in research with insulin secretion, gastric emptying, and satiety signaling.
- GIP receptor — the other major incretin receptor, studied for its role in insulin response, adipose-tissue function, and lipid handling.
Tirzepatide is described in the literature as a single peptide engineered from the GIP sequence to activate both receptors simultaneously. Researchers have investigated this dual approach for how the complementary actions of the two incretin pathways combine within one molecule — an idea reviewed in detail by the compound's original developers.
GLP-2 TRZ vs. single and triple receptor agonists
The clearest way to place GLP-2 TRZ in context is by the number of receptors each research compound targets. As a dual agonist, it sits between the single-receptor GLP-1 agonists and the newer triple agonists. The table below summarizes the incretin landscape researchers reference most often:
| Compound | GLP-1 | GIP | Glucagon | Class |
|---|---|---|---|---|
| GLP-2 TRZ (Tirzepatide) | ✓ | ✓ | — | Dual agonist |
| GLP-3 RT (Retatrutide) | ✓ | ✓ | ✓ | Triple agonist |
| Semaglutide | ✓ | — | — | Single (GLP-1) agonist |
| Cagrilintide (CAGRI) | — | — | — | Amylin analog |
The distinction from the triple-agonist class is the glucagon receptor: GLP-2 TRZ engages the two incretin receptors, while the triple agonist adds glucagon as a third target. For that compound, see the companion guide on GLP-3 RT. Peptora carries research-grade versions of several of these compounds, each with its own batch-specific certificate of analysis, including GLP-2 TRZ, GLP-3 RT, and Cagrilintide (CAGRI).
What the research explores
In laboratory settings, GLP-2 TRZ is most often studied across a handful of interconnected areas:
- Metabolism — how simultaneous GIP and GLP-1 signaling influences glucose and lipid handling in research models.
- Appetite regulation — satiety and food-intake signaling associated with incretin-receptor activity.
- Body-weight models — composition and weight endpoints in preclinical research.
- Incretin pharmacology — how combining two incretin receptors in one molecule differs from engaging either pathway alone.
Purity, testing, and certificates of analysis
In research, the reliability of a result depends on the identity and purity of the material behind it. Every batch of GLP-2 TRZ from Peptora is HPLC-verified to 99%+ purity, confirmed by LC-MS identity testing, and screened across a full quality-control panel before release. Each order ships with a lot-specific certificate of analysis (COA) so the material can be matched to its documentation.
Researchers often choose Peptora precisely because this documentation is standard rather than optional. To understand what each figure on a report means, see the guide on purity and certificates of analysis and the overview of testing standards.
Handling GLP-2 TRZ in the laboratory
GLP-2 TRZ is supplied as a lyophilized (freeze-dried) powder. For research use it is reconstituted with bacteriostatic water, which is sold separately. Careful handling preserves peptide integrity and the validity of downstream work:
- 1Allow the sealed vial to reach room temperature before opening.
- 2Add bacteriostatic water slowly against the vial wall; swirl gently and do not shake.
- 3Let the powder dissolve fully before drawing.
- 4Store the reconstituted solution refrigerated and protected from light.
Full step-by-step protocols live in the reconstitution guide and the storage guide. Following them consistently is one of the simplest ways to keep research reproducible.
Scientific references
Tirzepatide (LY3298176) has been investigated extensively in Eli Lilly-sponsored clinical trials — most notably the SURPASS programme in type 2 diabetes and the SURMOUNT programme in obesity — alongside mechanism-focused and review literature. The sources below are provided for educational context, per PubMed, ChEMBL, and ClinicalTrials.gov, and describe clinical and mechanistic research on the compound — not the laboratory research product supplied by Peptora.
- 1Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 (SURPASS-2; ClinicalTrials.gov: NCT03987919).
- 2Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (SURMOUNT-1; NCT04184622).
- 3Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. doi:10.1016/j.tem.2020.02.006.
- 4Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. doi:10.1186/s12933-022-01604-7.
- 5Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. doi:10.3389/fendo.2024.1431292.
- 6Melson E, et al. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024;49(3):433-451. doi:10.1038/s41366-024-01473-y.
Explore research-grade GLP-2 TRZ
HPLC-verified to 99%+ purity, batch-specific COA, fast U.S. shipping — for laboratory research use only.
View GLP-2 TRZKey takeaways
- GLP-2 TRZ is Peptora's research designation for Tirzepatide, a single-molecule dual-receptor agonist that engages both the GIP and GLP-1 receptors.
- Tirzepatide was originally developed by Eli Lilly as LY3298176 (marketed as Mounjaro and Zepbound); Peptora supplies GLP-2 TRZ strictly as a research-only material, not a medicine.
- Its defining feature is combining two incretin pathways in one peptide, placing it between single-receptor GLP-1 agonists and triple agonists such as GLP-3 RT (Retatrutide).
- It is studied in metabolic, appetite, and body-weight research models, and is for laboratory research use only.
- Peptora's GLP-2 TRZ is HPLC-verified to 99%+ purity with a lot-specific certificate of analysis in every order.
- It ships as a lyophilized powder and is reconstituted with bacteriostatic water before research use.
Frequently asked questions
This article is intended solely as an educational summary of publicly available scientific literature. Products offered by Peptora are supplied exclusively for laboratory research purposes and are not approved for human or veterinary use. The information presented should not be interpreted as medical advice, treatment recommendations, or clinical guidance.
